IN8bio, Inc. (INAB)

Market Cap	35.67M
Revenue (ttm)	n/a
Net Income (ttm)	-31.04M
Shares Out	44.12M
EPS (ttm)	-0.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	196,181
Open	0.831
Previous Close	0.813
Day's Range	0.761 - 0.843
52-Week Range	0.650 - 2.480
Beta	0.14
Analysts	Strong Buy
Price Target	8.83 (+992.42%)
Earnings Date	Aug 8, 2024

About INAB

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: INAB

Analyst Forecast

According to 3 analysts, the average rating for INAB stock is "Strong Buy." The 12-month stock price forecast is $8.83, which is an increase of 992.42% from the latest price.

Price Target

$8.83

(992.42% upside)

Analyst Consensus: Strong Buy